Catapult Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Catapult Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	$3.12M	Buy	+30,000	New	+$3.85M	1.18%	21

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Catapult Capital Management's VRTX Position: Q3 2015 in Review

Catapult Capital Management opened a new position in Vertex Pharmaceuticals (VRTX) in Q3 2015: 30,000 shares worth $3.12M. The stake represents 1.18% of the portfolio and ranks #21 among its holdings.

494 funds tracked by Wall St. Rank hold VRTX as of Q3 2015.

Catapult Capital Management held 30,000 shares of Vertex Pharmaceuticals worth $3.12M as of Q3 2015.
Vertex Pharmaceuticals was a new Catapult Capital Management position in Q3 2015.
Vertex Pharmaceuticals made up 1.18% of Catapult Capital Management's portfolio in Q3 2015, its #21 holding.
494 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2015.

Based on Catapult Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.